Abstract: Pharmaceutical compositions are disclosed that include a double-stranded RNAi agent that modulates LPA expression or its pharmaceutically acceptable salt thereof in water. Doses and dosing regimens for such RNAi agents also are disclosed that include administering doses from about 4 mg to about 608 mg at a frequency of monthly to yearly.
| # | Name | Date |
|---|---|---|
| 1 | 202517066465-STATEMENT OF UNDERTAKING (FORM 3) [11-07-2025(online)].pdf | 2025-07-11 |
| 3 | 202517066465-Sequence Listing in PDF [11-07-2025(online)].pdf | 2025-07-11 |
| 4 | 202517066465-PRIORITY DOCUMENTS [11-07-2025(online)].pdf | 2025-07-11 |
| 5 | 202517066465-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [11-07-2025(online)].pdf | 2025-07-11 |
| 6 | 202517066465-MARKED COPIES OF AMENDEMENTS [11-07-2025(online)].pdf | 2025-07-11 |
| 7 | 202517066465-FORM 18 [11-07-2025(online)].pdf | 2025-07-11 |
| 8 | 202517066465-FORM 13 [11-07-2025(online)].pdf | 2025-07-11 |
| 9 | 202517066465-FORM 1 [11-07-2025(online)].pdf | 2025-07-11 |
| 10 | 202517066465-FIGURE OF ABSTRACT [11-07-2025(online)].pdf | 2025-07-11 |
| 11 | 202517066465-DECLARATION OF INVENTORSHIP (FORM 5) [11-07-2025(online)].pdf | 2025-07-11 |
| 12 | 202517066465-COMPLETE SPECIFICATION [11-07-2025(online)].pdf | 2025-07-11 |
| 13 | 202517066465-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [11-07-2025(online)].pdf | 2025-07-11 |
| 14 | 202517066465-AMMENDED DOCUMENTS [11-07-2025(online)].pdf | 2025-07-11 |
| 15 | 202517066465-Proof of Right [22-07-2025(online)].pdf | 2025-07-22 |
| 16 | 202517066465-FORM-26 [22-07-2025(online)].pdf | 2025-07-22 |